SAREPTA THERAPEUTICS, INC. Contracts Revenue (Deprecated 2018-01-31)
SAREPTA THERAPEUTICS, INC. (SRPT) reported Contracts Revenue (Deprecated 2018-01-31) of $1.25 million for the 3-month period ending 2015-12-31, per its 10-K filed 2017-02-28.
Discontinued › Income Statement › Other Income
us-gaap:ContractsRevenue · last filed 2018-03-01
- SAREPTA THERAPEUTICS, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2015-12-31 was $1.25M, a 4540.74% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $27.00K, a 98.97% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2014-09-30 was $1.06M, a 74.59% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2014-06-30 was $2.58M, a 12.47% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2015 was $1.25M, a 87.16% decline from fiscal 2014.
- SAREPTA THERAPEUTICS, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2014 was $9.76M, a 31.38% decline from fiscal 2013.
- SAREPTA THERAPEUTICS, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2013 was $14.22M, a 61.91% decline from fiscal 2012.
- SAREPTA THERAPEUTICS, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2012 was $37.33M, a 20.56% decline from fiscal 2011.
| Period end | Contracts Revenue (Deprecated 2018-01-31) 3 month | Contracts Revenue (Deprecated 2018-01-31) 6 month | Contracts Revenue (Deprecated 2018-01-31) 9 month | Contracts Revenue (Deprecated 2018-01-31) 12 month | Contracts Revenue (Deprecated 2018-01-31) 395 month | Contracts Revenue (Deprecated 2018-01-31) 398 month | Contracts Revenue (Deprecated 2018-01-31) 401 month | Contracts Revenue (Deprecated 2018-01-31) 404 month |
|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | $1.25M 10-K · filed 2017-02-28 | $1.25M 10-K · filed 2018-03-01 | ||||||
| 2014-12-31 | $27.00K 10-K · filed 2016-02-25 | $1.09M derived: sum of 2 quarters · filed 2016-02-25 | $3.67M derived: sum of 3 quarters · filed 2016-02-25 | $9.76M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $1.06M 10-K · filed 2016-02-25 | $3.64M derived: sum of 2 quarters · filed 2016-02-25 | $9.73M 10-Q · filed 2015-11-05 | $12.36M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $2.58M 10-K · filed 2016-02-25 | $8.67M 10-Q · filed 2015-08-06 | $11.30M derived: sum of 3 quarters · filed 2016-02-25 | $15.46M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $6.09M 10-K · filed 2016-02-25 | $8.71M derived: sum of 2 quarters · filed 2016-02-25 | $12.88M derived: sum of 3 quarters · filed 2016-02-25 | $15.83M derived: sum of 4 quarters · filed 2016-02-25 | $193.85M 10-Q · filed 2014-05-08 | |||
| 2013-12-31 | $2.63M 10-K · filed 2015-02-26 | $6.79M derived: sum of 2 quarters · filed 2015-02-26 | $9.74M derived: sum of 3 quarters · filed 2015-02-26 | $14.22M 10-K · filed 2016-02-25 | $187.77M 10-K · filed 2014-03-03 | |||
| 2013-09-30 | $4.17M 10-Q · filed 2014-11-06 | $7.12M derived: sum of 2 quarters · filed 2015-02-26 | $11.59M 10-Q · filed 2014-11-06 | $18.93M derived: sum of 4 quarters · filed 2015-02-26 | $185.14M 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $2.95M 10-K · filed 2015-02-26 | $7.42M 10-Q · filed 2014-08-07 | $14.76M derived: sum of 3 quarters · filed 2015-02-26 | $22.34M derived: sum of 4 quarters · filed 2015-02-26 | $180.97M 10-Q · filed 2013-08-08 | |||
| 2013-03-31 | $4.47M 10-K · filed 2015-02-26 | $11.81M derived: sum of 2 quarters · filed 2015-02-26 | $19.38M derived: sum of 3 quarters · filed 2015-02-26 | $30.59M derived: sum of 4 quarters · filed 2015-02-26 | ||||
| 2012-12-31 | $7.34M 10-K · filed 2014-03-03 | $14.91M derived: sum of 2 quarters · filed 2014-03-03 | $26.12M derived: sum of 3 quarters · filed 2014-03-03 | $37.33M 10-K · filed 2015-02-26 | ||||
| 2012-09-30 | $7.57M 10-K · filed 2014-03-03 | $18.78M derived: sum of 2 quarters · filed 2014-03-03 | $29.99M 10-Q · filed 2013-11-12 | $43.58M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-06-30 | $11.21M 10-K · filed 2014-03-03 | $22.42M 10-Q · filed 2013-08-08 | $36.00M derived: sum of 3 quarters · filed 2014-03-03 | $43.53M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-03-31 | $11.21M 10-K · filed 2014-03-03 | $24.80M derived: sum of 2 quarters · filed 2014-03-03 | $32.32M derived: sum of 3 quarters · filed 2014-03-03 | $43.91M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2011-12-31 | $13.59M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $21.11M derived: sum of 2 quarters · filed 2014-03-03 | $32.69M derived: sum of 3 quarters · filed 2014-03-03 | $46.99M 10-K · filed 2014-03-03 | ||||
| 2011-09-30 | $7.52M 10-Q · filed 2012-11-07 | $19.11M derived: sum of 2 quarters · filed 2012-11-07 | $33.41M 10-Q · filed 2012-11-07 | |||||
| 2011-06-30 | $11.59M 10-Q · filed 2012-08-07 | $25.88M 10-Q · filed 2012-08-07 | ||||||
| 2010-12-31 | $29.42M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |